PR Newswire Clinical TrialsOriginal article
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Phase 2Nu-3Positive
AI Analysis
Summary
Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial of Nu-3 for infected diabetic foot ulcers, leveraging its proprietary Bisphosphocin antimicrobial platform. Topline data is expected in Q1 2027.
Clinical Trial Data
Phase
2a
Outcome Details
First patient dosed in Phase 2a clinical trial
Importance:5/10
Sentiment:
0.60
clinical-trialphase-2antimicrobialdiabetic-foot-ulcersbisphosphocin-platform
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 24, 2026 12:02 PM